Seres Therapeutics (MCRB) EBIT (2016 - 2025)
Historic EBIT for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to -$22.5 million.
- Seres Therapeutics' EBIT rose 2294.48% to -$22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.4 million, marking a year-over-year increase of 2013.39%. This contributed to the annual value of -$121.3 million for FY2024, which is 3781.81% up from last year.
- Latest data reveals that Seres Therapeutics reported EBIT of -$22.5 million as of Q3 2025, which was up 2294.48% from -$24.9 million recorded in Q2 2025.
- In the past 5 years, Seres Therapeutics' EBIT ranged from a high of $68.4 million in Q3 2021 and a low of -$70.6 million during Q1 2023
- Its 5-year average for EBIT is -$28.6 million, with a median of -$34.4 million in 2024.
- As far as peak fluctuations go, Seres Therapeutics' EBIT soared by 32806.13% in 2021, and later plummeted by 203887.93% in 2023.
- Quarter analysis of 5 years shows Seres Therapeutics' EBIT stood at -$49.4 million in 2021, then skyrocketed by 96.5% to -$1.7 million in 2022, then plummeted by 2038.88% to -$37.0 million in 2023, then rose by 22.12% to -$28.8 million in 2024, then increased by 22.05% to -$22.5 million in 2025.
- Its EBIT was -$22.5 million in Q3 2025, compared to -$24.9 million in Q2 2025 and -$27.2 million in Q1 2025.